CoChat
Sign Up
Cited by 5

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

miRNA375-3p/rapamycin mediates the mTOR pathway by decreasing PS1, enhances microglial cell activity to regulate autophagy in Alzheimer's disease

Wang, Yuxiang, Xiao, Zixuan, Yin, Hanlan, Ren, Zhichao, Ma, Xueting, Wang, Yibo, Zhang, Yan, Fu, Xueqi, Zhang, Fuqiang, Zeng, Linlin·2024·Heliyon
DOI 10.1016/j.heliyon.2024.e37589PMC PMC11461998
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.heliyon.2024.e37589

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 13 references

Research works printed but not linked: 30

  1. 2023, vol. 19, 1598
  2. Cummings, 2019, The "rights" of precision drug development for Alzheimer's disease, Alzheimer's Res. Ther., 11, 76, 10.1186/s13195-019-0529-5 · DOI
  3. Xia, 2021, "Don't Phos over Tau": recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer's disease and other tauopathies, Mol. Neurodegener., 16, 37, 10.1186/s13024-021-00460-5 · DOI
  4. Rabin, 2018, Interactive associations of Vascular risk and beta-amyloid Burden with cognitive decline in clinically normal elderly individuals: findings from the harvard aging brain study, JAMA Neurol., 75, 1124, 10.1001/jamaneurol.2018.1123 · DOI · Paper page
  5. Gu, 2019, Genetic influences on white matter and metabolism abnormal change in Alzheimer's disease: meta-analysis for neuroimaging research on presenilin 1 mutation, Clin. Neurol. Neurosurg., 177, 47, 10.1016/j.clineuro.2018.12.016 · DOI
  6. Zhang, 2022, Impairment of the autophagy-lysosomal pathway in Alzheimer's diseases: pathogenic mechanisms and therapeutic potential, Acta Pharm. Sin. B, 12, 1019, 10.1016/j.apsb.2022.01.008 · DOI
  7. Davoody, 2023, mTOR signaling and Alzheimer's disease: what we know and where we are?, CNS Neurosci. Ther.
  8. Morawe, 2022, Pharmacological mTOR-inhibition facilitates clearance of AD-related tau aggregates in the mouse brain, Eur. J. Pharmacol., 934, 10.1016/j.ejphar.2022.175301 · DOI
  9. Liu, 2021, Geniposide protection against Abeta(1-42) toxicity correlates with mTOR inhibition and enhancement of autophagy, J. Integr. Neurosci., 20, 67, 10.31083/j.jin.2021.01.242 · DOI
  10. Amin, 2023, Autophagy prevents microglial senescence, Nat. Cell Biol., 25, 923, 10.1038/s41556-023-01168-y · DOI
  11. Fujikawa, 2023, The functions and phenotypes of microglia in Alzheimer's disease, Cells-Basel, 12
  12. Chakrabarty, 2012, Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition, Mol. Neurodegener., 7, 36, 10.1186/1750-1326-7-36 · DOI · Paper page
  13. Hussen, 2021, MicroRNA: a signature for cancer progression, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 138
  14. Guevremont, 2022, Plasma microRNA vary in association with the progression of Alzheimer's disease, Alzheimer's Dementia, 14
  15. Wang, 2023, The potential of targeting microRNA-23b-3p signaling in Alzheimer's disease: opinions on recent findings, Front. Pharmacol., 14
  16. Bekris, 2015, The biomarker and therapeutic potential of miRNA in Alzheimer's disease, Neurodegener. Dis. Manag., 5, 61, 10.2217/nmt.14.52 · DOI
  17. Mall, 2013, Stability of miRNA in human urine supports its biomarker potential, Biomarkers Med., 7, 623, 10.2217/bmm.13.44 · DOI
  18. Zhai, 2021, ADMSC Exo-MicroRNA-22 improve neurological function and neuroinflammation in mice with Alzheimer's disease, J. Cell Mol. Med., 25, 7513, 10.1111/jcmm.16787 · DOI
  19. Mai, 2019, Intranasal administration of miR-146a agomir rescued the pathological process and cognitive impairment in an AD mouse model, molecular therapy, Nucleic acids, 18, 681, 10.1016/j.omtn.2019.10.002 · DOI
  20. Kim, 2018, The microRNA miR-7a-5p ameliorates ischemic brain damage by repressing α-synuclein, Sci. Signal., 11, 10.1126/scisignal.aat4285 · DOI
  21. Yu, 2021, MicroRNA-99b-3p promotes angiotensin II-induced cardiac fibrosis in mice by targeting GSK-3β, Acta Pharmacol. Sin., 42, 715, 10.1038/s41401-020-0498-z · DOI
  22. Song, 2022, MicroRNA-210 controls mitochondrial metabolism and protects heart function in myocardial infarction, Circulation, 145, 1140, 10.1161/CIRCULATIONAHA.121.056929 · DOI
  23. Zhang, 2018, Metformin synergizes with rapamycin to inhibit the growth of pancreatic cancer in vitro and in vivo, Oncol. Lett., 15, 1811
  24. Othman, 2021, Morris water maze: a versatile and pertinent tool for assessing spatial learning and memory, Exp Anim Tokyo, 71, 264, 10.1538/expanim.21-0120 · DOI
  25. Li, 2014, Rapamycin: one drug, many effects, Cell Metab, 19, 373, 10.1016/j.cmet.2014.01.001 · DOI · Paper page
  26. Wei, 2022, Different phenotypes of microglia in animal models of Alzheimer disease, Immun. Ageing, 19, 10.1186/s12979-022-00300-0 · DOI
  27. Schmukler, 2020, Autophagy induction in the treatment of Alzheimer's disease, Drug Dev. Res., 81, 184, 10.1002/ddr.21605 · DOI
  28. Scheltens, 2021, Alzheimer's disease, Lancet, 397, 1577, 10.1016/S0140-6736(20)32205-4 · DOI · Paper page
  29. Marques-Ramos, 2023, Expression of mTOR in normal and pathological conditions, Mol. Cancer, 22, 10.1186/s12943-023-01820-z · DOI
  30. Tang, 2016, Differential roles of M1 and M2 microglia in neurodegenerative diseases, Mol. Neurobiol., 53, 1181, 10.1007/s12035-014-9070-5 · DOI · Paper page

Cited by

Sorted by citations

See all 5

Metadata

Authors
Wang, Y., Xiao, Z., Yin, H., Ren, Z., Ma, X., Wang, Y., Zhang, Y., Fu, X., Zhang, F., & Zeng, L.
ORCID
Zeng, Linlin
Venue
Heliyon
Publisher
Elsevier BV
Published
2024-10
Volume
10
Issue
19
Pages
e37589
ISSN
2405-8440
DOI
10.1016/j.heliyon.2024.e37589
PMC
PMC11461998
Cited by
5
References
13
Language
en
Licence
Funders
  • Department of Science and Technology of Jilin Province (YDZJ202301ZYTS536)
  • National Key Research and Development Program of China (2021YFA1500400)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review